GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)

Procurement Inclusion Criteria:

* 1\) Diagnosis of GPC3-positive recurrent ATRT.
* 2\) Age ≥ 6 months
* 3\) Karnofsky/Lansky score ≥ 60%
* 4\) Informed consent explained to, understood by, and signed by patient/guardian; copy provided
* 5\) GPC3 expression by immunohistochemistry with extent score ≥ Grade 2 (\>25% positive tumor cells) and intensity score ≥ 2 (scale 0-4)

Procurement Exclusion Criteria:

* 1\) No history of organ transplantation
* 2\) No known HIV positivity
* 3\) No active bacterial, fungal, or viral infection (except Hepatitis B or Hepatitis C virus infections)
* 4\) No other risk factors in which administration of the investigational agent is deemed not in the patient's best interest, in the opinion of the investigator

Treatment Inclusion Criteria:

* 1\) Age ≥ 6 months
* 2\) Diagnosis of treatment refractory or unresectable ATRT after standard of care therapy
* 3\) Lansky/Karnofsky score ≥ 60%
* 4\) Stable neurologic exam for 7 days prior to enrollment
* 5\) Stable or decreasing dose of steroids over past 7 days prior to surgery and administration of therapy (max allowable dose is 0.1mg/kg dexamethasone or equivalent per day)
* 6\) Not receiving any concurrent anti-cancer therapy.
* 7\) At least 6 weeks following craniospinal radiation therapy.
* 8\) At least 14 days wash-out needed following small volume radiotherapy (i.e., Stereotactic Radiosurgery (SRS)).
* 9\) At least 21 days or 5 half-lives (whichever is shorter) must have elapsed since any prior systemic therapy
* 10\) Received any other forms of immunotherapy ≤ 42 days before administration of investigational agent
* 11\) At least 28 days following bevacizumab
* 12\) Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml/min
* 13\) Total bilirubin \< 3 times ULN for age
* 14\) INR ≤ 1.7
* 15\) Absolute neutrophil count \> 500/μl
* 16\) Platelet count \> 100,000/μl (can be transfused but must be achieved prior to enrollment)
* 17\) Hgb ≥ 7.0 g/dl (can be transfused)
* 18\) Pulse oximetry \> 90% on room air
* 19\) Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study
* 20\) Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion.
* 21\) Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent

Treatment Exclusion Criteria:

* 1\) Pregnancy or lactation (for women at child-bearing age, birth control is required)
* 2\) Uncontrolled infection
* 3\) Known HIV positivity
* 4\) Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)
* 5\) History of organ transplantation